Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience

BACKGROUND: Upfront docetaxel or novel hormonal agents (NHA) such as abiraterone and enzalutamide have become the standard of care for metastatic hormone sensitive prostate cancer (mHSPC). We evaluated real-world management of patients treated with these agents at a single center. PATIENTS AND METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Guin, Sunny, Liaw, Bobby K., Jun, Tomi, Ayers, Kristin, Patel, Bonny, O’Connell, Timmy, Deitz, Matthew, Klein, Michael, Mullaney, Tommy, Prentice, Tony, Newman, Scott, Fink, Marc, Zhou, Xiang, Schadt, Eric E., Chen, Rong, Oh, William K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390935/
https://www.ncbi.nlm.nih.gov/pubmed/35984843
http://dx.doi.org/10.1371/journal.pone.0264800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390935/
https://www.ncbi.nlm.nih.gov/pubmed/35984843
http://dx.doi.org/10.1371/journal.pone.0264800

Ejemplares similares